BRPI0717767A2 - Composto, composição farmacêutica, e, métodos para tratar ou prevenir câncer, uma condição inflamatória, uma condição imunológica ou uma condição metabólica, e para inibir uma quinase em uma célula de expressa a dita quinase - Google Patents

Composto, composição farmacêutica, e, métodos para tratar ou prevenir câncer, uma condição inflamatória, uma condição imunológica ou uma condição metabólica, e para inibir uma quinase em uma célula de expressa a dita quinase

Info

Publication number: BRPI0717767A2
Authority: BR; Brazil
Prior art keywords: condition; kinase; treating; methods; compound
Prior art date: 2006-10-19

Application number

BRPI0717767-4A2A

Other languages

English (en)

Inventor

Deborah Sue Mortensen

Maria Mercedes Delgado Mederos

John Joseph Sapienza

Ronald J Albers

Branden G Lee

Roy Leonard Harris

Graziella Isabel Shevlin

Dehua Huang

Kimberly Lyn Schwarz

Garrick K Packard

Jason Simon Parnes

Patrick William Papa

Lida Radnia Tehrani

Sophie Perrin-Ninkovic

Original Assignee

Signal Pharm Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-10-19

Filing date

2007-10-18

Publication date

2013-11-12

2007-10-18 Application filed by Signal Pharm Llc filed Critical Signal Pharm Llc

2013-11-12 Publication of BRPI0717767A2 publication Critical patent/BRPI0717767A2/pt

Links

108091000080 Phosphotransferase Proteins 0.000 title abstract 3
102000020233 phosphotransferase Human genes 0.000 title abstract 3
206010028980 Neoplasm Diseases 0.000 title abstract 2
201000011510 cancer Diseases 0.000 title abstract 2
230000001900 immune effect Effects 0.000 title abstract 2
230000004968 inflammatory condition Effects 0.000 title abstract 2
230000002503 metabolic effect Effects 0.000 title abstract 2
150000001875 compounds Chemical class 0.000 title 1
230000002401 inhibitory effect Effects 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
-1 Heteroaryl Compound Chemical class 0.000 abstract 2
125000001072 heteroaryl group Chemical group 0.000 abstract 1
230000005764 inhibitory process Effects 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
230000037361 pathway Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Immunology (AREA)
Hematology (AREA)
Obesity (AREA)
Rheumatology (AREA)
Neurology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Otolaryngology (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Child & Adolescent Psychology (AREA)
Biomedical Technology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Plural Heterocyclic Compounds (AREA)

BRPI0717767-4A2A 2006-10-19 2007-10-18 Composto, composição farmacêutica, e, métodos para tratar ou prevenir câncer, uma condição inflamatória, uma condição imunológica ou uma condição metabólica, e para inibir uma quinase em uma célula de expressa a dita quinase BRPI0717767A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US85316606P	2006-10-19	2006-10-19
PCT/US2007/022374 WO2008051493A2 (en)	2006-10-19	2007-10-18	Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors

Publications (1)

Publication Number	Publication Date
BRPI0717767A2 true BRPI0717767A2 (pt)	2013-11-12

Family

ID=39144386

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0717767-4A2A BRPI0717767A2 (pt)	2006-10-19	2007-10-18	Composto, composição farmacêutica, e, métodos para tratar ou prevenir câncer, uma condição inflamatória, uma condição imunológica ou uma condição metabólica, e para inibir uma quinase em uma célula de expressa a dita quinase

Country Status (16)

Country	Link
US (2)	US7981893B2 (pt)
EP (3)	EP2090577B1 (pt)
JP (1)	JP5513118B2 (pt)
KR (2)	KR101504669B1 (pt)
CN (2)	CN105693730A (pt)
AT (1)	ATE543819T1 (pt)
AU (1)	AU2007309467B2 (pt)
BR (1)	BRPI0717767A2 (pt)
CA (1)	CA2666618C (pt)
ES (3)	ES2627352T3 (pt)
IL (1)	IL198115A (pt)
MX (2)	MX2009004077A (pt)
NZ (1)	NZ576278A (pt)
RU (1)	RU2478635C2 (pt)
WO (1)	WO2008051493A2 (pt)
ZA (1)	ZA200902382B (pt)

Families Citing this family (159)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7989459B2 (en)	2006-02-17	2011-08-02	Pharmacopeia, Llc	Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
US8227603B2 (en)	2006-08-01	2012-07-24	Cytokinetics, Inc.	Modulating skeletal muscle
BRPI0714725B1 (pt)	2006-08-02	2021-05-25	Cytokinetics, Inc	Entidade química, composição farmaceuticamente aceitável, e, uso de uma entidade química
US8299248B2 (en) *	2006-08-02	2012-10-30	Cytokinetics, Incorporated	Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
TW200831104A (en)	2006-10-04	2008-08-01	Pharmacopeia Inc	6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
US7902187B2 (en)	2006-10-04	2011-03-08	Wyeth Llc	6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
TW200837064A (en)	2006-10-04	2008-09-16	Pharmacopeia Inc	8-substituted 2-(benzimidazolyl)purine derivatives for immunosuppression
ES2627352T3 (es)	2006-10-19	2017-07-27	Signal Pharmaceuticals, Llc	Compuestos heteroarilo, sus composiciones y su uso como inhibidores de proteínas quinasas
US7851484B2 (en)	2007-03-30	2010-12-14	Cytokinetics, Inc.	Certain chemical entities, compositions, and methods
US8173635B2 (en)	2007-11-02	2012-05-08	Vertex Pharmaceuticals Incorporated	Kinase inhibitors
US7998976B2 (en) *	2008-02-04	2011-08-16	Cytokinetics, Inc.	Certain chemical entities, compositions and methods
CA2713864A1 (en) *	2008-02-04	2009-08-13	Cytokinetics, Incorporated	Certain chemical entities, compositions and methods
AU2009226136B2 (en)	2008-03-17	2013-08-15	Ambit Biosciences Corporation	Quinazoline derivatives as RAF kinase modulators and methods of use thereof
US9273077B2 (en)	2008-05-21	2016-03-01	Ariad Pharmaceuticals, Inc.	Phosphorus derivatives as kinase inhibitors
JP2011523646A (ja)	2008-05-21	2011-08-18	アリアド・ファーマシューティカルズ・インコーポレイテッド	キナーゼ阻害剤としてのリン誘導体
DK2308877T3 (da)	2008-08-05	2014-04-22	Daiichi Sankyo Co Ltd	Imidazopyridin-2-on-derivater
US20110190365A1 (en) *	2008-08-14	2011-08-04	Bayer Crop Science Ag	Insecticidal 4-phenyl-1H-pyrazoles
EP2341052A4 (en) *	2008-09-05	2011-10-12	Shionogi & Co	RING-CONDENSED MORPHOLINE DERIVATIVITY WITH PI3K-INHIBITING EFFECT
TWI378933B (en)	2008-10-14	2012-12-11	Daiichi Sankyo Co Ltd	Morpholinopurine derivatives
US8110578B2 (en)	2008-10-27	2012-02-07	Signal Pharmaceuticals, Llc	Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
AU2014208199B2 (en) *	2008-10-27	2015-12-03	Signal Pharmaceuticals, Llc	Mtor kinase inhibitors for oncology indications and diseases associated with the mtor/p13k/akt pathway
JP5590040B2 (ja) *	2008-11-12	2014-09-17	アリアド・ファーマシューティカルズ・インコーポレイテッド	キナーゼ阻害剤としてのピラジノピラジンおよび誘導体
CN102264743B (zh)	2008-11-25	2015-02-11	罗彻斯特大学	Mlk抑制剂及其使用方法
UY32306A (es)	2008-12-09	2010-07-30	Gilead Sciences Inc	Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos
PL3354650T3 (pl)	2008-12-19	2022-06-13	Vertex Pharmaceuticals Incorporated	Związki przydatne jako inhibitory kinazy atr
RU2636614C2 (ru) *	2009-05-19	2017-11-24	Вивия Байотек С.Л.	Способы персонализированного медицинского тестирования ex vivo на гематологические новообразования
WO2011031965A1 (en)	2009-09-14	2011-03-17	Gilead Sciences, Inc.	Modulators of toll-like receptors
NZ599549A (en) *	2009-10-26	2013-11-29	Signal Pharm Llc	Methods of synthesis and purification of heteroaryl compounds
JP5759471B2 (ja)	2009-10-29	2015-08-05	ヴェクチュラリミテッド	Ｊａｋ３キナーゼ阻害剤としての窒素含有ヘテロアリール誘導体
EP2516434B1 (en)	2009-12-23	2015-05-27	Takeda Pharmaceutical Company Limited	Fused heteroaromatic pyrrolidinones as syk inhibitors
EP2582702A1 (en) *	2010-01-27	2013-04-24	Vertex Pharmaceuticals Incorporated	Pyrazolopyrimidine kinase inhibitors
BR112012019459A2 (pt)	2010-02-03	2017-10-17	Signal Pharm Llc	identificação de mutação de lkb1 como um biomarcador preditivo para sensibilidade para inibidores de tor quinase.
WO2011096490A1 (ja) *	2010-02-04	2011-08-11	第一三共株式会社	イミダゾピリジン－２－オン誘導体
US9138309B2 (en)	2010-02-05	2015-09-22	Allergan, Inc.	Porous materials, methods of making and uses
US9205577B2 (en) *	2010-02-05	2015-12-08	Allergan, Inc.	Porogen compositions, methods of making and uses
US11202853B2 (en) *	2010-05-11	2021-12-21	Allergan, Inc.	Porogen compositions, methods of making and uses
US8962631B2 (en)	2010-05-12	2015-02-24	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
WO2011143423A2 (en) *	2010-05-12	2011-11-17	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
JP2013526540A (ja)	2010-05-12	2013-06-24	バーテックスファーマシューティカルズインコーポレイテッド	Ａｔｒキナーゼ阻害剤として有用な化合物
JP2013526538A (ja)	2010-05-12	2013-06-24	バーテックスファーマシューティカルズインコーポレイテッド	Ａｔｒキナーゼ阻害剤として有用な化合物
JP5836367B2 (ja)	2010-05-12	2015-12-24	バーテックスファーマシューティカルズインコーポレイテッドＶｅｒｔｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃｏｒｐｏｒａｔｅｄ	Ａｔｒキナーゼ阻害剤として有用な化合物
CN103154246B (zh)	2010-05-14	2015-11-25	达那-法伯癌症研究所	用于治疗白血病的组合物和方法
ES2606958T3 (es)	2010-05-14	2017-03-28	Dana-Farber Cancer Institute, Inc.	Compuestos de tienotriazolodiazepina para tratar una neoplasia
CN103180318B (zh)	2010-05-14	2017-05-10	达那-法伯癌症研究所	雄性避孕组合物以及使用方法
EP2576549A4 (en) *	2010-05-24	2013-12-18	Univ Rochester	Bicyclic Heteroarylkinase Inhibitors and Methods of Use
US20120028972A1 (en) *	2010-07-30	2012-02-02	Lilly Wong	Biomarker assays for detecting or measuring inhibition of tor kinase activity
JP5990106B2 (ja) *	2011-01-28	2016-09-07	佐藤製薬株式会社	縮環化合物
AU2012250517B2 (en)	2011-05-04	2016-05-19	Takeda Pharmaceutical Company Limited	Compounds for inhibiting cell proliferation in EGFR-driven cancers
EP2527344A1 (en)	2011-05-25	2012-11-28	Almirall, S.A.	Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
JP2014522818A (ja)	2011-06-22	2014-09-08	バーテックスファーマシューティカルズインコーポレイテッド	Ａｔｒキナーゼ阻害剤として有用な化合物
WO2012178125A1 (en)	2011-06-22	2012-12-27	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
WO2012177714A1 (en)	2011-06-22	2012-12-27	Takeda Pharmaceutical Company Limited	Substituted 6-aza-isoindolin-1-one derivatives
CN109316480A (zh)	2011-07-13	2019-02-12	赛特凯恩蒂克公司	组合als疗法
RU2018147217A (ru)	2011-09-30	2019-01-18	Вертекс Фармасьютикалз Инкорпорейтед	Способы получения соединений, которые можно использовать в качестве ингибиторов киназы atr
AU2012315384B2 (en)	2011-09-30	2017-08-10	Vertex Pharmaceuticals Incorporated	Treating pancreatic cancer and non-small cell lung cancer with ATR inhibitors
AU2012318272B2 (en) *	2011-10-19	2015-06-11	Signal Pharmaceuticals, Llc	Treatment of cancer with TOR kinase inhibitors
CN103998036B (zh) *	2011-10-19	2017-05-31	西格诺药品有限公司	利用tor激酶抑制剂治疗癌症
BR112014013332B1 (pt)	2011-12-02	2022-09-06	Signal Pharmaceuticals, Llc	Composições farmacêuticas de 7-(6-(2-hidroxi-propan-2-il)piridin-3-il)-1-((trans)-4- metoxicicloexil)-3,4-diidropirazino [2,3-b]pirazin-2(1h)-ona, uma forma sólida dessa e métodos de seu uso
IN2014CN04174A (pt)	2011-12-22	2015-09-04	Novartis Ag
CN104271159B (zh)	2012-02-24	2017-11-28	西格诺药品有限公司	利用tor激酶抑制剂联合治疗来治疗非小细胞肺癌的方法
EP2825169B1 (en)	2012-03-15	2018-05-09	Signal Pharmaceuticals, LLC	Treatment of cancer with tor kinase inhibitors
EA028414B1 (ru) *	2012-03-15	2017-11-30	СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи	Лечение рака ингибиторами tor киназы
ES2668279T3 (es) *	2012-03-15	2018-05-17	Signal Pharmaceuticals, Llc	Tratamiento del cáncer con inhibidores de la cinasa TOR
EP2825168B1 (en) *	2012-03-15	2018-05-09	Signal Pharmaceuticals, LLC	Treatment of cancer with tor kinase inhibitors
AU2015201138B2 (en) *	2012-03-15	2016-06-23	Signal Pharmaceuticals, Llc	Treatment of cancer with TOR kinase inhibitors
CN104321322A (zh) *	2012-03-30	2015-01-28	理森制药股份公司	作为c-met蛋白激酶调节剂的新型3,5-二取代-3h-咪唑并[4,5-b]吡啶和3,5-二取代-3h-[1,2,3]三唑并[4,5-b]吡啶化合物
CN104582795B (zh)	2012-04-05	2018-04-20	沃泰克斯药物股份有限公司	可用作atr激酶抑制剂的化合物及其组合疗法
JP6469567B2 (ja)	2012-05-05	2019-02-13	アリアド・ファーマシューティカルズ・インコーポレイテッド	Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
EP2890698B1 (en) *	2012-08-30	2017-03-01	F. Hoffmann-La Roche AG	Dioxino- and oxazin-[2,3-d]pyrimidine pi3k inhibitor compounds and methods of use
DK2904406T3 (en)	2012-10-04	2018-06-18	Vertex Pharma	METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE
US8912198B2 (en)	2012-10-16	2014-12-16	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
EA039396B1 (ru) *	2012-10-18	2022-01-24	СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи	Лечение рака молочной железы с тройным негативным фенотипом ингибиторами tor-киназы
AU2013203714B2 (en)	2012-10-18	2015-12-03	Signal Pharmaceuticals, Llc	Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
AU2013202768B2 (en)	2012-10-18	2015-11-05	Signal Pharmaceuticals, Llc	Treatment of cancer with TOR kinase inhibitors
US10106778B2 (en)	2012-11-08	2018-10-23	Whitehead Institute For Biomedical Research	Selective targeting of cancer stem cells
US10485800B2 (en)	2012-11-30	2019-11-26	The University Of Rochester	Mixed lineage kinase inhibitors for HIV/AIDS therapies
LT3418281T (lt)	2012-12-07	2021-01-11	Vertex Pharmaceuticals Inc.	Pirazolo[1,5-a]pirimidinai, naudotini kaip atr kinazės inhibitoriai, skirti vėžinių ligų gydymui
JP2016504990A (ja) *	2012-12-20	2016-02-18	バイエルファーマアクチエンゲゼルシャフト	Ｂｅｔタンパク質抑制性ジヒドロピリドピラジノン
SG11201505446WA (en)	2013-01-16	2015-08-28	Signal Pharm Llc	Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
AU2014223501A1 (en)	2013-02-28	2015-09-17	Signal Pharmaceuticals, Llc	Treatment of cancer with TOR kinase inhibitors
WO2014159392A1 (en)	2013-03-14	2014-10-02	Dana-Farber Cancer Institute, Inc.	Bromodomain binding reagents and uses thereof
WO2014143240A1 (en)	2013-03-15	2014-09-18	Vertex Pharmaceuticals Incorporated	Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
US9611283B1 (en)	2013-04-10	2017-04-04	Ariad Pharmaceuticals, Inc.	Methods for inhibiting cell proliferation in ALK-driven cancers
HK1221168A1 (zh)	2013-04-17	2017-05-26	西格诺药品有限公司	用於治疗癌症的包括tor激酶抑制剂和n-(3-(5-氟-2-(4-(2-甲氧基乙氧基)苯基氨基)嘧啶-4-基氨基)苯基)丙烯醯胺的组合疗法
EP3549940A1 (en)	2013-04-17	2019-10-09	Signal Pharmaceuticals, LLC	Pharmaceutical formulations, of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
WO2014172436A1 (en) *	2013-04-17	2014-10-23	Signal Pharmaceuticals, Llc	Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
US20140314673A1 (en) *	2013-04-17	2014-10-23	Signal Pharmaceuticals, Llc	Treatment of cancer with dihydropyrazino-pyrazines
JP6382946B2 (ja)	2013-04-17	2018-08-29	シグナルファーマシューティカルズ，エルエルシー	ジヒドロピラジノ−ピラジンによる癌治療
CA2908742C (en) *	2013-04-17	2021-06-01	Signal Pharmaceuticals, Llc	Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
MY189663A (en) *	2013-04-17	2022-02-23	Signal Pharm Llc	Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
WO2014172425A1 (en) *	2013-04-17	2014-10-23	Signal Pharmaceuticals, Llc	Treatment of cancer with dihydropyrazino-pyrazines
CN107474051B (zh)	2013-05-29	2020-10-30	西格诺药品有限公司	二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途
PE20160664A1 (es)	2013-06-27	2016-07-09	Pfizer	Compuestos heteroaromaticos y su uso como ligandos d1 de dopamina
BR112016001457A2 (pt)	2013-07-25	2017-08-29	Dana Farber Cancer Inst Inc	Inibidores de fatores de transcrição e usos dos mesmos
AU2014331049B2 (en) *	2013-10-04	2018-03-29	Torqur Ag	Conformationally restricted PI3K and mTOR inhibitors
GB2586924B (en) *	2013-11-08	2021-06-02	Halliburton Energy Services Inc	Copolymer surfactants for use in downhole fluids
US11446309B2 (en)	2013-11-08	2022-09-20	Dana-Farber Cancer Institute, Inc.	Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors
HUE046727T2 (hu)	2013-12-06	2020-03-30	Vertex Pharma	Az ATR-kináz inhibitoraként használható vegyület, 2-amino-6-fluoro-N-[5-fluoro-piridin-3-IL]-pirazolo-[1,5-A]-pirimidin-3-karboxamid, ennek elõállítása, különbözõ szilárd formái és ezek radioaktív nyomjelzett származékai
WO2015117083A1 (en) *	2014-01-31	2015-08-06	Dana-Farber Cancer Institute, Inc.	Diazepane derivatives and uses thereof
EP3099693A4 (en)	2014-01-31	2017-08-16	Dana-Farber Cancer Institute, Inc.	Uses of diazepane derivatives
KR20160111520A (ko) *	2014-01-31	2016-09-26	다나-파버 캔서 인스티튜트 인크.	디히드로프테리디논 유도체 및 그의 용도
MX2016009974A (es)	2014-01-31	2016-10-31	Dana Farber Cancer Inst Inc	Derivados de diaminopirimidina bencensulfona y sus usos.
WO2015131113A1 (en)	2014-02-28	2015-09-03	Tensha Therapeutics, Inc.	Treatment of conditions associated with hyperinsulinaemia
RU2564015C1 (ru) *	2014-03-17	2015-09-27	Общество С Ограниченной Ответственностью "Фарма Старт"	Фармацевтическая композиция производных гаммааминомасляной кислоты для твердых капсул
EP3131552B1 (en)	2014-04-16	2020-07-15	Signal Pharmaceuticals, LLC	Methods for treating cancer using tor kinase inhibitor combination therapy
NZ714742A (en)	2014-04-16	2017-04-28	Signal Pharm Llc	Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
WO2015160880A1 (en)	2014-04-16	2015-10-22	Signal Pharmaceuticals, Llc	SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
US9718824B2 (en)	2014-04-16	2017-08-01	Signal Pharmaceuticals, Llc	Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof
US10398672B2 (en)	2014-04-29	2019-09-03	Whitehead Institute For Biomedical Research	Methods and compositions for targeting cancer stem cells
ES2777608T3 (es)	2014-06-05	2020-08-05	Vertex Pharma	Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útiles como inhibidores de ATR cinasa, la preparación de dicho compuesto y diferentes formas sólidas del mismo
US11179394B2 (en)	2014-06-17	2021-11-23	Vertex Pharmaceuticals Incorporated	Method for treating cancer using a combination of Chk1 and ATR inhibitors
SI3166607T1 (sl)	2014-07-11	2023-01-31	Gilead Sciences, Inc.	Modulatorji toličnih receptorjev za zdravljenje HIV-a
WO2016010886A1 (en)	2014-07-14	2016-01-21	Signal Pharmaceuticals, Llc	Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
NZ629796A (en)	2014-07-14	2015-12-24	Signal Pharm Llc	Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
WO2016022970A1 (en)	2014-08-08	2016-02-11	Dana-Farber Cancer Institute, Inc.	Dihydropteridinone derivatives and uses thereof
RU2017104897A (ru)	2014-08-08	2018-09-10	Дана-Фарбер Кэнсер Инститьют, Инк.	Производные диазепана и их применения
CN110305133A (zh)	2014-09-16	2019-10-08	吉利德科学公司	Toll样受体调节剂的固体形式
CN107074860B (zh)	2014-09-16	2022-07-15	吉利德科学公司	制备toll样受体调节剂的方法
UA122130C2 (uk)	2014-10-27	2020-09-25	Тенша Терапеутікс, Інк.	Інгібітори бромодомену
ES2779532T3 (es)	2015-04-08	2020-08-18	Bayer Cropscience Ag	Derivados de imidazo[1,2a]piridin-2-ilo como pesticidas y sus productos intermedios
UY36629A (es)	2015-04-17	2016-11-30	Abbvie Inc	Indazolonas como moduladores de la señalización de tnf
AR104291A1 (es)	2015-04-17	2017-07-12	Abbvie Inc	Moduladores tricíclicos de la señalización por tnf
EP3286195A1 (en)	2015-04-17	2018-02-28	AbbVie Inc.	Indazolones as modulators of tnf signaling
GB201509893D0 (en) *	2015-06-08	2015-07-22	Ucb Biopharma Sprl	Therapeutic agents
CA2986441A1 (en)	2015-06-12	2016-12-15	Dana-Farber Cancer Institute, Inc.	Combination therapy of transcription inhibitors and kinase inhibitors
WO2016210403A1 (en) *	2015-06-26	2016-12-29	The Regents Of The University Of Michigan	G protein-coupled receptor kinase inhibitors and methods for use of the same
WO2017040982A1 (en) *	2015-09-02	2017-03-09	The Regents Of The University Of California	Her3 ligands and uses thereof
US11306105B2 (en)	2015-09-11	2022-04-19	Dana-Farber Cancer Institute, Inc.	Cyano thienotriazolodiazepines and uses thereof
RU2018112953A (ru)	2015-09-11	2019-10-14	Дана-Фарбер Кэнсер Инститьют, Инк.	Ацетамидтиенотриазолодиазепины и пути их применения
US11464774B2 (en)	2015-09-30	2022-10-11	Vertex Pharmaceuticals Incorporated	Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
CN108430986B (zh)	2015-10-26	2021-08-31	拜耳作物科学股份公司	作为有害生物控制剂的稠合双环杂环衍生物
CR20180336A (es)	2015-11-25	2018-08-06	Dana Farber Cancer Inst Inc	Inhibidores de bromodominio bivalentes y usos de los mismos
TWI808055B (zh)	2016-05-11	2023-07-11	美商滬亞生物國際有限公司	Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh)	2016-05-11	2023-03-01	美商滬亞生物國際有限公司	Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
WO2018036469A1 (zh) *	2016-08-22	2018-03-01	南京明德新药研发股份有限公司	Pde4抑制剂
WO2018102455A1 (en)	2016-12-01	2018-06-07	Ignyta, Inc.	Methods for the treatment of cancer
DK3558997T3 (da)	2016-12-20	2021-04-19	Astrazeneca Ab	Aminotriazolopyridinforbindelser og deres anvendelse til behandling af cancer
TW201823231A (zh)	2016-12-28	2018-07-01	大陸商江蘇恆瑞醫藥股份有限公司	氮雜雙環基取代的三唑類衍生物、其製備方法及其在醫藥上的應用
WO2018138050A1 (de)	2017-01-26	2018-08-02	Bayer Aktiengesellschaft	Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
WO2018183868A1 (en) *	2017-03-31	2018-10-04	Bioventures, Llc	Inhibitors of dna pk and uses thereof
IL271491B2 (en)	2017-06-22	2023-09-01	Celgene Corp	Treatment of carcinoma of the liver characterized by hepatitis b virus infection
WO2019035866A1 (en) *	2017-08-15	2019-02-21	The Brigham & Women's Hospital, Inc.	COMPOSITIONS AND METHODS FOR TREATING THE TUBEROUS SCLEROSIS COMPLEX
CA3080509A1 (en)	2017-11-01	2019-05-09	Juno Therapeutics, Inc.	Process for producing a t cell composition
WO2019134539A1 (zh) *	2018-01-05	2019-07-11	四川科伦博泰生物医药股份有限公司	二氢吡唑酮并嘧啶类化合物及其制备方法和用途
CN112105357A (zh) *	2018-02-16	2020-12-18	Ucb生物制药有限责任公司	药用6,5杂双环衍生物
BR112020018286A2 (pt)	2018-03-09	2020-12-29	Recurium Ip Holdings, Llc	1,2-di-hidro-3h-pirazolo[3,4-d]pirimidin-3-onas substituídas
WO2019189731A1 (ja)	2018-03-30	2019-10-03	住友化学株式会社	複素環化合物及びそれを含有する有害節足動物防除組成物
CN110386932A (zh)	2018-04-20	2019-10-29	艾科思莱德制药公司	用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
LT3860998T (lt) *	2018-10-05	2024-06-25	Annapurna Bio Inc.	Junginiai ir kompozicijos, skirti gydyti būkles, susijusias su apj receptoriaus aktyvumu
US11952328B2 (en)	2018-10-17	2024-04-09	The Research Foundation For The State University Of New York	Selective ship inhibitors for treating disease
CN113924114A (zh)	2019-05-22	2022-01-11	吉利德科学公司	Tlr7调节化合物和hiv疫苗的组合
BR112022023559A2 (pt) *	2020-05-21	2023-01-24	Stemsynergy Therapeutics Inc	Inibidores de notch e seus usos
CN111982875A (zh) *	2020-08-20	2020-11-24	北京大学深圳研究院	一种基于三维荧光光谱分析的产聚羟基脂肪酸酯菌的筛选方法
WO2022159852A1 (en) *	2021-01-25	2022-07-28	Icahn School Of Medicine At Mount Sinai	Methods and compositions for treating adenoid cystic carcinoma
US12599625B2 (en)	2021-05-13	2026-04-14	Penland Foundation	Treatment of ARDS and other conditions caused by acutely elevated cytokine levels and post ARDS chronic cytokine production using inhaled anesthetics
WO2023287726A1 (en)	2021-07-12	2023-01-19	Penland Foundation	Treatment of cancer using botulinum toxin and nitrous oxide
CN120787258A (zh)	2023-02-07	2025-10-14	圭尔医疗有限公司	Treg细胞培养方法
GB202411558D0 (en)	2024-08-06	2024-09-18	Quell Therapeutics Ltd	Culture method
CN119529271B (zh) *	2024-11-25	2025-12-05	湖北理工学院	一种光敏剂载体及其制备方法和应用

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3507866A (en) *	1967-08-08	1970-04-21	Merck & Co Inc	1h - imidazo(4,5-b)pyrazin - 2 - one and processes for their preparation
US3567725A (en) *	1968-11-20	1971-03-02	Merck & Co Inc	Process for preparation of 1h-imidazo-(4,5-b)pyrazin-2-ones
US4294837A (en) *	1980-03-28	1981-10-13	Sterling Drug Inc.	1,3-Dihydro-6-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones and -imidazo[4,5-b]pyridine-2-thiones and their cardiotonic use
US4317909A (en) *	1980-03-24	1982-03-02	Sterling Drug Inc.	Preparation of 1,3-dihydro-5-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones
US4294836A (en) *	1980-03-24	1981-10-13	Sterling Drug Inc.	1,3-Dihydro-6-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones and -imidazo[4,5-b]-pyridine-2-thiones and their cardiotonic use
US4309537A (en) *	1980-03-28	1982-01-05	Sterling Drug Inc.	Production of imidazo[4,5-b]pyridin-2-ones or thiones
US4859672A (en) *	1986-10-29	1989-08-22	Rorer Pharmaceutical Corporation	Pyrido[2,3-d]pyrimidinone and imidazo[4,5-b]pyrimidinone
GB8709448D0 (en) *	1987-04-21	1987-05-28	Pfizer Ltd	Heterobicyclic quinoline derivatives
JPS63275582A (ja)	1987-05-02	1988-11-14	Naade Kenkyusho:Kk	２−アミノイミダゾ〔４，５−ｂ〕ピリジン誘導体の製造方法
DD262026A1 (de) *	1987-07-10	1988-11-16	Akad Wissenschaften Ddr	Verfahren zur herstellung von 4-substituierten 6-(pyrid-4-yl)-2,4-dihydro-1h-imidazo[4,5-b]pyrid-2-onen
FR2643903A1 (fr)	1989-03-03	1990-09-07	Union Pharma Scient Appl	Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux
US4963561A (en) *	1990-02-28	1990-10-16	Sterling Drug Inc.	Imidazopyridines, their preparation and use
TW274550B (pt) *	1992-09-26	1996-04-21	Hoechst Ag
WO1995003009A1 (en)	1993-07-22	1995-02-02	Oculex Pharmaceuticals, Inc.	Method of treatment of macular degeneration
WO1995003807A1 (en)	1993-07-27	1995-02-09	The University Of Sydney	Treatment of age-related macular degeneration
TW574214B (en) *	1994-06-08	2004-02-01	Pfizer	Corticotropin releasing factor antagonists
IT1274549B (it)	1995-05-23	1997-07-17	Indena Spa	Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno
DE19601627A1 (de) *	1996-01-18	1997-07-24	Bayer Ag	Heteroatomhaltige Cyclopentanopyridyl-Oxazolidinone
US5800819A (en)	1996-01-25	1998-09-01	National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology	Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease
JP4667543B2 (ja) *	1996-07-03	2011-04-13	大日本住友製薬株式会社	新規プリン誘導体
US5635517B1 (en)	1996-07-24	1999-06-29	Celgene Corp	Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US6281230B1 (en)	1996-07-24	2001-08-28	Celgene Corporation	Isoindolines, method of use, and pharmaceutical compositions
US5693641A (en) *	1996-08-16	1997-12-02	Berlex Laboratories Inc.	Bicyclic pyrimidine derivatives and their use as anti-coagulants
TW477787B (en) *	1996-08-27	2002-03-01	Pfizer	Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
PL332040A1 (en)	1996-08-28	1999-08-16	Pfizer	Substitution 6,5-heterobicyclic derivatives
US20010007867A1 (en)	1999-12-13	2001-07-12	Yuhpyng L. Chen	Substituted 6,5-hetero-bicyclic derivatives
RU2230553C2 (ru) *	1997-09-26	2004-06-20	Центарис АГ	Способ модулирования функции серин/треонин протеинкиназы соединением на основе азабензимидазола, способ идентификации соединений, модулирующих функцию серин/треонин протеинкиназы, способ профилактики или лечения патологических состояний в организме, соединение на основе азабензимидазола, способ его синтеза и фармацевтическая композиция
ZA9810490B (en)	1997-12-03	1999-05-20	Dainippon Pharmaceutical Co	2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor
TW572758B (en) *	1997-12-22	2004-01-21	Sumitomo Pharma	Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
US6015803A (en)	1998-05-04	2000-01-18	Wirostko; Emil	Antibiotic treatment of age-related macular degeneration
US6225348B1 (en)	1998-08-20	2001-05-01	Alfred W. Paulsen	Method of treating macular degeneration with a prostaglandin derivative
US6001368A (en)	1998-09-03	1999-12-14	Protein Technologies International, Inc.	Method for inhibiting or reducing the risk of macular degeneration
JP2003146987A (ja)	1999-05-31	2003-05-21	Dainippon Pharmaceut Co Ltd	２−アリールプリン−９−アセトアミド誘導体
JP3814125B2 (ja) *	1999-06-02	2006-08-23	大日本住友製薬株式会社	２−アリール−８−オキソジヒドロプリン誘導体からなる医薬
FR2804431A1 (fr)	2000-02-02	2001-08-03	Adir	Nouveaux derives heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP4272338B2 (ja) *	2000-09-22	2009-06-03	バイエルアクチェンゲゼルシャフト	ピリジン誘導体
JP2002167387A (ja)	2000-11-29	2002-06-11	Dainippon Pharmaceut Co Ltd	２−（７，８−ジヒドロ−８−オキソ−９ｈ−プリン−９−イル）酢酸誘導体
JP2004520299A (ja) *	2000-12-12	2004-07-08	ニューロジェン・コーポレーション	スピロ［イソベンゾフラン−１，４’−ピペリジン］−３−オン類及び３ｈ−スピロイソベンゾフラン−１，４’−ピペリジン類
US20040235867A1 (en) *	2001-07-24	2004-11-25	Bilodeau Mark T.	Tyrosine kinase inhibitors
UY27427A1 (es)	2001-09-04	2003-03-31	Boehringer Ingelheim Pharma	Nuevas dihidro-pteridinonas, procedimientos para su preparación y su utilización como medicamentos
WO2003032989A1 (en)	2001-10-18	2003-04-24	Boehringer Ingelheim Pharmaceuticals, Inc.	1,4-disubstituted benzo-fused urea compounds as cytokine inhibitors
AU2003299531A1 (en) *	2002-08-05	2004-06-07	University Of Massachusetts	Compounds for modulating rna interference
EP1590341B1 (en)	2003-01-17	2009-06-17	Warner-Lambert Company LLC	2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
US6861422B2 (en) *	2003-02-26	2005-03-01	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
DE50307267D1 (de)	2003-02-26	2007-06-21	Boehringer Ingelheim Pharma	Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
GB2400101A (en) *	2003-03-28	2004-10-06	Biofocus Discovery Ltd	Compounds capable of binding to the active site of protein kinases
US7476665B2 (en) *	2003-06-26	2009-01-13	Merck & Co., Inc.	Benzodiazepine CGRP receptor antagonists
JP4775259B2 (ja) *	2004-03-31	2011-09-21	味の素株式会社	アニリン誘導体
ES2241496B1 (es) *	2004-04-15	2006-12-01	Almirall Prodesfarma, S.A.	Nuevos derivados de piridina.
JP2008501707A (ja)	2004-06-04	2008-01-24	アイコス、コーポレーション	マスト細胞障害を処置するための方法
DE102004029784A1 (de) *	2004-06-21	2006-01-05	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
WO2006001266A1 (ja)	2004-06-23	2006-01-05	Banyu Pharmaceutical Co., Ltd.	２－アリールプリン誘導体の製造方法
DE102004033670A1 (de) *	2004-07-09	2006-02-02	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US20060035903A1 (en) *	2004-08-14	2006-02-16	Boehringer Ingelheim International Gmbh	Storage stable perfusion solution for dihydropteridinones
US20060058311A1 (en) *	2004-08-14	2006-03-16	Boehringer Ingelheim International Gmbh	Combinations for the treatment of diseases involving cell proliferation
US20060074088A1 (en) *	2004-08-14	2006-04-06	Boehringer Ingelheim International Gmbh	Dihydropteridinones for the treatment of cancer diseases
EP1630163A1 (de) *	2004-08-25	2006-03-01	Boehringer Ingelheim Pharma GmbH & Co.KG	Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
WO2006021548A1 (de) *	2004-08-27	2006-03-02	Boehringer Ingelheim International Gmbh	Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
GB0420719D0 (en)	2004-09-17	2004-10-20	Addex Pharmaceuticals Sa	Novel allosteric modulators
AU2005289644A1 (en)	2004-09-24	2006-04-06	Janssen Pharmaceutica, N.V.	Imidazo{4,5-b}pyrazinone inhibitors of protein kinases
UY29177A1 (es) *	2004-10-25	2006-05-31	Astex Therapeutics Ltd	Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
BRPI0517272A (pt)	2004-10-29	2008-10-07	Tibotec Pharm Ltd	derivados de pirimidina bicìclicos de inibição de hiv
US7767687B2 (en)	2004-12-13	2010-08-03	Biogen Idec Ma Inc.	Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors
JP5190271B2 (ja) *	2005-01-14	2013-04-24	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	キナーゼ阻害剤としての５員の環付加複素環式ピリミジン
KR20070104936A (ko) *	2005-02-16	2007-10-29	아스트라제네카 아베	화합물
WO2006091737A1 (en) *	2005-02-24	2006-08-31	Kemia, Inc.	Modulators of gsk-3 activity
BRPI0610514A2 (pt) *	2005-04-05	2016-11-16	Pharmacopeia Inc	composto, composição farmacêutica, e, método de tratamento de um distúrbio
ES2270715B1 (es) *	2005-07-29	2008-04-01	Laboratorios Almirall S.A.	Nuevos derivados de pirazina.
ES2274712B1 (es) *	2005-10-06	2008-03-01	Laboratorios Almirall S.A.	Nuevos derivados imidazopiridina.
BRPI0714725B1 (pt) *	2006-08-02	2021-05-25	Cytokinetics, Inc	Entidade química, composição farmaceuticamente aceitável, e, uso de uma entidade química
ES2627352T3 (es)	2006-10-19	2017-07-27	Signal Pharmaceuticals, Llc	Compuestos heteroarilo, sus composiciones y su uso como inhibidores de proteínas quinasas
CN102264743B (zh)	2008-11-25	2015-02-11	罗彻斯特大学	Mlk抑制剂及其使用方法

2007
- 2007-10-18 ES ES09006829.7T patent/ES2627352T3/es active Active
- 2007-10-18 KR KR1020097010205A patent/KR101504669B1/ko active Active
- 2007-10-18 EP EP09006829.7A patent/EP2090577B1/en active Active
- 2007-10-18 US US11/975,652 patent/US7981893B2/en active Active
- 2007-10-18 MX MX2009004077A patent/MX2009004077A/es active IP Right Grant
- 2007-10-18 CA CA2666618A patent/CA2666618C/en active Active
- 2007-10-18 AU AU2007309467A patent/AU2007309467B2/en active Active
- 2007-10-18 KR KR1020147023019A patent/KR20140104060A/ko not_active Abandoned
- 2007-10-18 BR BRPI0717767-4A2A patent/BRPI0717767A2/pt not_active IP Right Cessation
- 2007-10-18 CN CN201610018106.3A patent/CN105693730A/zh active Pending
- 2007-10-18 RU RU2009118623/04A patent/RU2478635C2/ru not_active IP Right Cessation
- 2007-10-18 WO PCT/US2007/022374 patent/WO2008051493A2/en not_active Ceased
- 2007-10-18 EP EP12152100.9A patent/EP2457913B1/en active Active
- 2007-10-18 CN CNA2007800468221A patent/CN101573360A/zh active Pending
- 2007-10-18 ES ES12152100.9T patent/ES2631003T3/es active Active
- 2007-10-18 JP JP2009533397A patent/JP5513118B2/ja active Active
- 2007-10-18 MX MX2012001823A patent/MX337906B/es unknown
- 2007-10-18 ZA ZA200902382A patent/ZA200902382B/xx unknown
- 2007-10-18 EP EP07861467A patent/EP2078016B1/en active Active
- 2007-10-18 NZ NZ576278A patent/NZ576278A/en not_active IP Right Cessation
- 2007-10-18 AT AT07861467T patent/ATE543819T1/de active
- 2007-10-18 ES ES07861467T patent/ES2381215T3/es active Active
2009
- 2009-04-07 IL IL198115A patent/IL198115A/en active IP Right Grant
2011
- 2011-06-09 US US13/156,462 patent/US8372976B2/en active Active

Also Published As

Publication number	Publication date
JP5513118B2 (ja)	2014-06-04
EP2078016A2 (en)	2009-07-15
MX337906B (es)	2016-03-28
EP2090577A2 (en)	2009-08-19
KR20090082407A (ko)	2009-07-30
RU2009118623A (ru)	2010-11-27
EP2457913A3 (en)	2012-08-15
KR20140104060A (ko)	2014-08-27
EP2457913A2 (en)	2012-05-30
EP2457913B1 (en)	2017-04-19
US20110245245A1 (en)	2011-10-06
HK1131145A1 (en)	2010-01-15
RU2478635C2 (ru)	2013-04-10
WO2008051493A3 (en)	2008-07-03
CA2666618A1 (en)	2008-05-02
JP2010506934A (ja)	2010-03-04
ES2627352T3 (es)	2017-07-27
US20090023724A1 (en)	2009-01-22
US7981893B2 (en)	2011-07-19
MX2009004077A (es)	2009-05-05
AU2007309467A1 (en)	2008-05-02
ATE543819T1 (de)	2012-02-15
WO2008051493A2 (en)	2008-05-02
NZ576278A (en)	2011-12-22
EP2090577B1 (en)	2017-04-05
EP2090577A3 (en)	2009-08-26
ES2631003T3 (es)	2017-08-25
US8372976B2 (en)	2013-02-12
EP2090577A8 (en)	2015-02-11
ES2381215T3 (es)	2012-05-24
IL198115A (en)	2015-02-26
KR101504669B1 (ko)	2015-03-20
CA2666618C (en)	2015-12-29
CN101573360A (zh)	2009-11-04
IL198115A0 (en)	2009-12-24
EP2078016B1 (en)	2012-02-01
AU2007309467B2 (en)	2013-07-18
CN105693730A (zh)	2016-06-22
ZA200902382B (en)	2010-08-25

Legal Events

Date	Code	Title	Description
2018-04-24	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-08-14	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
2018-12-04	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2484 DE 14-08-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
BRPI0717773A2 (pt)	2013-11-05	Composto, composição farmacêutica, e, métodos para tratar ou prevenir câncer, uma condição inflamatória, uma condição imunológica ou uma condição metabólica, e para inibir uma quinase em uma célula que expressa a dita quinase
ZA200902382B (en)	2010-08-25	Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors
WO2008036308A3 (en)	2008-05-08	Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith
BRPI0515499A (pt)	2008-07-29	derivados de piridina para a inibição de estearoil-coa-desaturase humana
WO2009155121A3 (en)	2010-02-18	Inhibitors of pi3 kinase
WO2007084391A3 (en)	2008-03-20	Thiazole compounds as protein kinase b ( pkb) inhibitors
WO2007129195A3 (en)	2009-09-17	4-pyrimidine-5-amino-pyrazole compounds
WO2009027820A3 (en)	2009-04-23	Substituted-quinoxaline-type-piperidine compounds and the uses thereof
WO2008100867A3 (en)	2009-01-08	Novel inhibitors hepatitis c virus replication
WO2008116129A3 (en)	2009-02-12	Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors
MY159235A (en)	2016-12-30	Mtor kinase inhibitors for oncology indications and diseases associated with the mtor/p13k/akt pathway
WO2009097113A3 (en)	2009-10-22	Oxazole and thiazole compounds as b-catenin modulators and uses thereof
EA201001772A1 (ru)	2011-06-30	Производные 3,5-диамино-6-хлорпиразин-2-карбоновой кислоты и их применение в качестве блокаторов эпителиальных натриевых каналов для лечения заболеваний дыхательных путей
PL2397156T3 (pl)	2017-07-31	Sposoby i kompozycje do leczenia uporczywych infekcji i nowotworu poprzez hamowanie ścieżki zaprogramowanej śmierci komórki 1 (PD-1)
CO6531502A2 (es)	2012-09-28	Aminotriazolopiridinas y su uso como inhibidores de cinasa
TN2010000038A1 (en)	2011-09-26	Organic compounds
MX2011012614A (es)	2012-02-22	Compuestos de quetolida que tienen actividad antimicrobiana.
NO20085317L (no)	2009-02-05	Imidazoazepinonforbindelser
MX2008016358A (es)	2009-01-16	Derivados de tiazolil-urea como inhibidores de cinasa de fosfatidil-inositol-3.
TW200800993A (en)	2008-01-01	Organic compounds
WO2005105770A3 (en)	2006-03-09	Arylphenylamino-, arylphenylamide-, and arylphenylether-sulfide derivatives
WO2006108679A3 (en)	2007-02-22	Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use to combat cancer
WO2008080268A8 (zh)	2009-08-13	取代的酒石酸衍生物及其用于制备
WO2005105766A3 (en)	2006-01-26	Arylphenylamino-and arylphenylether-sulfide derivatives, useful for the treatment of inflammatory and immune diseases, and pharmaceutical compositions containing them
BR112012013723A2 (pt)	2018-01-23	"uso de pelo menos um composto de fórmula (i), método para conservar uma composição cosmética, dermatológica ou farmacêutica e composição cosmética, dermatológica ou farmacêutica"